Question 1

What are the main end-use segments for Osimertinib Mesylate, and what share of demand does each represent?

Accepted Answer

The main end-use segments are pharmaceuticals, representing approximately 95% to 98% of demand, and specialty chemicals and research, accounting for around 1% to 2%.

Question 2

What is the reaction or synthesis route and key intermediates used to manufacture Osimertinib Mesylate?

Accepted Answer

The process begins with Friedel-Crafts arylation of N-methylindole with dichloropyrimidine, followed by SNAr reactions with nitroaniline and N, N, N’-trimethylethylenediamine. The nitro group is then reduced using iron, followed by acylation and elimination with 3-chloropropanoyl chloride. The final step is mesylate salt formation.

Question 3

What are the key intermediate or API cost requirements, and what share of raw material cost do they represent?

Accepted Answer

Raw material procurement accounts for approximately 50% to 65% of total OPEX. Key cost items include N-methylindole, dichloropyrimidine, nitroaniline, N, N, N’-trimethylethylenediamine, 3-chloropropanoyl chloride, solvents, and other process reagents.

Question 4

What share of total capital cost do the core reaction and purification equipment represent?

Accepted Answer

The reaction section represents approximately 25% to 35% of total CAPEX, while purification and separation equipment accounts for around 20% to 25%.

Question 5

What factors drive Osimertinib Mesylate manufacturing cost the most?

Accepted Answer

Manufacturing costs are mainly driven by the prices of N-methylindole and dichloropyrimidine, specialty reagents such as nitroaniline and N, N, N’-trimethylethylenediamine, 3-chloropropanoyl chloride, solvents, process yield, and purification requirements.

Question 6

In which regions is Osimertinib Mesylate manufacturing capacity concentrated?

Accepted Answer

Manufacturing capacity for generic osimertinib mesylate is concentrated in the Asia-Pacific region, particularly China and India.

Question 7

What regulatory requirements (FDA, EMA, GMP, DMF filings) apply to Osimertinib Mesylate manufacturing?

Accepted Answer

Manufacturing requires strict compliance with cGMP standards, validated processes, quality testing, and pharmaceutical regulatory requirements. FDA or EMA submissions and DMF filings may be required when supplying regulated markets.

Osimertinib Mesylate Manufacturing Plant Project Report 2026: Cost Analysis, ROI, and Feasibility Insights

About the Author

Vishakha Agrawal

Frequently Asked Questions